Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of JS212 alone or in combination with JS207 or toripalimab in recurrent or metastatic triple-negative breast cancer
CTR20263812Phase 2Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Oct 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of JS212 in triple-negative breast cancer (TNBC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Oct 2026; status: active.
02
Drugs
JS212
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20263812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263812.